Published in Oncol Lett on August 06, 2012
A Toll-like receptor recognizes bacterial DNA. Nature (2000) 26.34
CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 12.24
Humanized mice in translational biomedical research. Nat Rev Immunol (2007) 8.83
NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood (2002) 7.78
Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol (1996) 2.74
Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol (2004) 2.48
Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity. J Immunol (1992) 2.02
Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol (1998) 1.94
CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine (2000) 1.80
Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1. Reduction in host defense against malignancy without loss of cellular or humoral immunity. J Immunol (1987) 1.78
IL-12 deaths: explanation and a puzzle. Science (1995) 1.58
Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res (1999) 1.38
The cytokine stew and innate resistance to L. monocytogenes. Immunol Rev (1997) 1.29
Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res (2000) 1.27
Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine (1999) 1.20
CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine (2000) 1.15
An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. J Lab Clin Med (1996) 1.07
CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res (2003) 1.03
Efficient engraftment of human primary breast cancer transplants in nonconditioned NOD/Scid mice. Int J Cancer (2003) 1.00
Adoptive immunotherapy of mucin1 expressing adenocarcinomas with mucin1 stimulated human peripheral blood mononuclear cells. Int J Mol Med (2002) 0.89
Growth inhibition of an orthotopic glioblastoma in immunocompetent mice by cationic lipid-DNA complexes. Cancer Immunol Immunother (2003) 0.85
Immunotherapy with low-dose recombinant interleukin 2 after high-dose chemotherapy and autologous stem cell transplantation in neuroblastoma. Br J Cancer (1998) 0.84
The influence of natural killer cells in neuroblastoma. Arch Surg (1989) 0.83
Prompt tumor formation and maintenance of constitutive NF-kappaB activity of multiple myeloma cells in NOD/SCID/gammacnull mice. Cancer Sci (2004) 0.83
A synthetic single-stranded DNA, poly(dG,dC), induces interferon-alpha/beta and -gamma, augments natural killer activity, and suppresses tumor growth. Jpn J Cancer Res (1988) 0.80
The role of STAT-3 in the induction of apoptosis in pancreatic cancer cells by benzyl isothiocyanate. J Natl Cancer Inst (2009) 2.30
Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species. J Biol Chem (2005) 2.28
Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits proliferation of human prostate cancer cells by causing G2/M arrest and inducing apoptosis. Carcinogenesis (2003) 2.20
Sulforaphane-induced G2/M phase cell cycle arrest involves checkpoint kinase 2-mediated phosphorylation of cell division cycle 25C. J Biol Chem (2004) 1.88
In vitro and in vivo induction of apoptosis by capsaicin in pancreatic cancer cells is mediated through ROS generation and mitochondrial death pathway. Apoptosis (2008) 1.44
Pancreatic tumor suppression by benzyl isothiocyanate is associated with inhibition of PI3K/AKT/FOXO pathway. Clin Cancer Res (2011) 1.42
Benzyl isothiocyanate-mediated generation of reactive oxygen species causes cell cycle arrest and induces apoptosis via activation of MAPK in human pancreatic cancer cells. Carcinogenesis (2009) 1.31
Role of mitochondrial electron transport chain complexes in capsaicin mediated oxidative stress leading to apoptosis in pancreatic cancer cells. PLoS One (2011) 1.23
Molecular targets of isothiocyanates in cancer: recent advances. Mol Nutr Food Res (2014) 1.08
Regulation of macroautophagy in ovarian cancer cells in vitro and in vivo by controlling glucose regulatory protein 78 and AMPK. Oncotarget (2012) 1.08
Benzyl isothiocyanate-induced DNA damage causes G2/M cell cycle arrest and apoptosis in human pancreatic cancer cells. J Nutr (2006) 1.06
Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models. BMC Med (2012) 1.03
Benzyl isothiocyanate suppresses pancreatic tumor angiogenesis and invasion by inhibiting HIF-α/VEGF/Rho-GTPases: pivotal role of STAT-3. PLoS One (2011) 1.02
Apoptosis signal-regulating kinase 1-thioredoxin complex dissociation by capsaicin causes pancreatic tumor growth suppression by inducing apoptosis. Antioxid Redox Signal (2012) 1.00
Benzyl isothiocyanate-mediated inhibition of histone deacetylase leads to NF-kappaB turnoff in human pancreatic carcinoma cells. Mol Cancer Ther (2010) 1.00
Betulinic acid derivatives as anticancer agents: structure activity relationship. Anticancer Agents Med Chem (2006) 1.00
CD8-mediated type 1 antitumor responses selectively modulate endogenous differentiated and nondifferentiated T cell localization, activation, and function in progressive breast cancer. J Immunol (2006) 1.00
Blocking epidermal growth factor receptor activation by 3,3'-diindolylmethane suppresses ovarian tumor growth in vitro and in vivo. J Pharmacol Exp Ther (2011) 0.99
Inhibition of chronic pancreatitis and pancreatic intraepithelial neoplasia (PanIN) by capsaicin in LSL-KrasG12D/Pdx1-Cre mice. Carcinogenesis (2011) 0.97
Membrane association of glutathione S-transferase mGSTA4-4, an enzyme that metabolizes lipid peroxidation products. J Biol Chem (2001) 0.96
Activation of checkpoint kinase 2 by 3,3'-diindolylmethane is required for causing G2/M cell cycle arrest in human ovarian cancer cells. Mol Pharmacol (2010) 0.95
Metastasis of Breast Tumor Cells to Brain Is Suppressed by Phenethyl Isothiocyanate in a Novel In Vivo Metastasis Model. PLoS One (2013) 0.95
Triphala inhibits both in vitro and in vivo xenograft growth of pancreatic tumor cells by inducing apoptosis. BMC Cancer (2008) 0.95
Inhibition of Integrin-HER2 signaling by Cucurbitacin B leads to in vitro and in vivo breast tumor growth suppression. Oncotarget (2014) 0.94
Diindolylmethane-mediated Gli1 protein suppression induces anoikis in ovarian cancer cells in vitro and blocks tumor formation ability in vivo. J Biol Chem (2012) 0.93
Betulinic acid and its derivatives as anti-angiogenic agents. Bioorg Med Chem Lett (2004) 0.93
CBP-mediated FOXO-1 acetylation inhibits pancreatic tumor growth by targeting SirT. Mol Cancer Ther (2014) 0.93
MHC-unrestricted lysis of MUC1-expressing cells by human peripheral blood mononuclear cells. Immunol Invest (2008) 0.90
Adoptive immunotherapy of mucin1 expressing adenocarcinomas with mucin1 stimulated human peripheral blood mononuclear cells. Int J Mol Med (2002) 0.89
Nanowire arrays in multicrystalline silicon thin films on glass: a promising material for research and applications in nanotechnology. Nano Lett (2012) 0.88
Inhibition of EGFR-AKT axis results in the suppression of ovarian tumors in vitro and in preclinical mouse model. PLoS One (2012) 0.88
RNF2 is the target for phosphorylation by the p38 MAPK and ERK signaling pathways. Proteomics (2009) 0.88
Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival. Clin Immunol (2009) 0.86
Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study. J Immunother (2012) 0.85
Caffeic acid phenethyl ester suppresses melanoma tumor growth by inhibiting PI3K/AKT/XIAP pathway. Carcinogenesis (2013) 0.84
Caspase-9 as a therapeutic target for treating cancer. Expert Opin Ther Targets (2014) 0.84
The role of K-ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines. Cancer Chemother Pharmacol (2010) 0.84
Structure-toxicity relationship of phenolic analogs as anti-melanoma agents: an enzyme directed prodrug approach. Chem Biol Interact (2009) 0.83
Immunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer. Cancer Immunol Immunother (2011) 0.81
Nanoemulsions of cancer chemopreventive agent benzyl isothiocyanate display enhanced solubility, dissolution, and permeability. J Agric Food Chem (2011) 0.81
Targeting migration inducting gene-7 inhibits carcinoma cell invasion, early primary tumor growth, and stimulates monocyte oncolytic activity. Mol Cancer Ther (2009) 0.81
BITC Sensitizes Pancreatic Adenocarcinomas to TRAIL-induced Apoptosis. Cancer Growth Metastasis (2010) 0.81
Tumor burden influences cytotoxic T cell development in metastatic breast cancer patients--a phase I/II study. Immunol Invest (2009) 0.80
Major effect of pyrrolic N-benzylation in norbinaltorphimine, the selective kappa-opioid receptor antagonist. J Med Chem (2005) 0.80
Critical role of allyl groups and disulfide chain in induction of Pi class glutathione transferase in mouse tissues in vivo by diallyl disulfide, a naturally occurring chemopreventive agent in garlic. Carcinogenesis (2002) 0.80
Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating differentiated T cell localization, activation and chemokine production in established breast cancer. Clin Immunol (2008) 0.79
Reactive intermediates produced from the metabolism of the vanilloid ring of capsaicinoids by p450 enzymes. Chem Res Toxicol (2012) 0.79
Synthesis of spiro[chroman-2,4'-piperidin]-4-one derivatives as acetyl-CoA carboxylase inhibitors. Bioorg Med Chem Lett (2008) 0.79
Synthesis and cytotoxic activity of 3-O-acyl/3-hydrazine /2-bromo/20,29-dibromo betulinic acid derivatives. Bioorg Med Chem Lett (2004) 0.79
Structural basis for catalytic differences between alpha class human glutathione transferases hGSTA1-1 and hGSTA2-2 for glutathione conjugation of environmental carcinogen benzo[a]pyrene-7,8-diol-9,10-epoxide. Biochemistry (2004) 0.79
Synthesis and evaluation of 4/5-hydroxy-2,3-diaryl(substituted)-cyclopent-2-en-1-ones as cis-restricted analogues of combretastatin A-4 as novel anticancer agents. J Med Chem (2007) 0.79
Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating endogenous CD49b-expressing CD4 and CD8 T effector cell subpopulations producing IL-10. Immunol Invest (2008) 0.78
Differential expression of glutathione S-transferase isoenzymes in murine small intestine and colon. Comp Biochem Physiol B Biochem Mol Biol (2002) 0.78
DIMming ovarian cancer growth. Curr Drug Targets (2012) 0.78
Retention of immunogenicity produced by mucin 1 peptides with glycosylation site substitutions. Immunopharmacol Immunotoxicol (2010) 0.77
Synthesis of 3-O-acyl/3-benzylidene/3-hydrazone/3-hydrazine/17-carboxyacryloyl ester derivatives of betulinic acid as anti-angiogenic agents. Bioorg Med Chem Lett (2004) 0.77
4-Isopropyl-5,5-dimethyl-2-sulfanyl-1,3,2-dioxaphosphinane 2-sulfide. Acta Crystallogr Sect E Struct Rep Online (2012) 0.75
Dendritic cells enhance the activity of human MUC1-stimulated mononuclear cells against breast cancer. Oncoimmunology (2013) 0.75
Extension of the Nenitzescu reaction to simple ketones provides an efficient route to 1'-alkyl-5'-hydroxynaltrindole analogues, potent and selective delta-opioid receptor antagonists. J Med Chem (2005) 0.75
Number of treatment cycles influences development of cytotoxic T cells in metastatic breast cancer patients - a phase I/II study. Immunol Invest (2010) 0.75
Tucaresol down-modulation of MUC1-stimulated human mononuclear cells. Immunol Invest (2013) 0.75